Q-linea is making progress, including commercial evaluations and partner discussions for the US market, and the Company are also confirming that the final stage of the FDA application is active. The actual reported Q3 result is very much in line with our expectations. The next step includes securing the first commercial orders, most likely in Italy or the UK, and confirming that the FDA is ready to approve ASTar. Our Q3 update includes a slight negative sales revision, a slight positive cost revision and our Base case valuation is SEK 9 (11), Bull SEK 35 (40) and Bear SEK 1 (2).

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/